The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
AB Science reported positive long-term survival data for masitinib treatment in ALS patients. The study showed a 5-year survival rate of 42.3%, representing a two-fold improvement over historical benchmarks. Additionally, 49% of long-term survivors maintained a satisfactory quality of life without the need for mechanical assistance. The median overall survival observed in masitinib-treated survivors was 121 months, compared to 42 months predicted by the ENCALS model.